Products & Ingredients

Clinical Study Demonstrates Magtein Improves Cognitive Health

A recent randomized, controlled, double-blind study published in the Journal of Alzheimer’s Disease concluded that nutritional supplementation with Magtein magnesium threonate from AIDP was effective at reversing cognitive impairment—and returned cognitive function almost back to normal ability relative to age.

Guosong Liu, MD, PhD, a former professor at the Massachusetts Institute of Technology, professor and founding director of the Center for Learning and Memory, School of Medicine, Tsinghua University, Beijing, said, “The loss of cognitive function is one of the greatest health fears of older adults. The Centers for Disease Control and Prevention (CDC) estimates that more than 16 million people live with it. Cognitive impairment adversely affects the quality of our daily lives, from stealing our memories to robbing us of basic daily physical activity.”

The study also demonstrated the safety and efficacy of magnesium threonate (Magtein), a compound designed to help magnesium to cross the blood-brain barrier so that it can increase brain synapse density and restoration of certain cognitive abilities. This study highlighted the importance of increasing neuronal intracellular magnesium, a key intermediary of synapse density control, for improving cognitive abilities in older adults. The effect of magnesium threonate on cognitive ability was evaluated in four cognitive domains: executive function, working memory, attention and episodic memory by administration of the Trail Making, Digit Span, Flanker, and Face-Name tests, respectively, at baseline, week 6 and week 12.

Following 12 weeks of Magtein use there was an average increase of 10.3 ± 3.8% in TMT-B speed, such that their speed was close to that of their age-matched controls. The data demonstrated that Magtein use was effective among subjects at improving cognitive ability almost back to normal levels relative to age. Subject population included 44 men and women between 50 and 70 years of age with self-reported memory loss and sleep disorder. The mean subject age was 57.3 ± 5.2 years, with 71% being female.

For more information: www.aidp.com

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Related Breaking News